ALAGILLE SYNDROME
Clinical trials for ALAGILLE SYNDROME explained in plain language.
Never miss a new study
Get alerted when new ALAGILLE SYNDROME trials appear
Sign up with your email to follow new studies for ALAGILLE SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study tracks Livmarli's Long-Term effects in rare liver disease
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of the drug Livmarli in people with Alagille syndrome, a rare genetic liver condition. About 100 patients who are already prescribed Livmarli will be followed to monitor side effects, liver function, and key health outcom…
Matched conditions: ALAGILLE SYNDROME
Phase: PHASE4 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 04:29 UTC
-
New hope for rare liver disease: long-term drug trial targets severe itching
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of odevixibat in people with Alagille syndrome, a rare genetic disorder that affects the liver and other organs. The drug is already approved in the US to treat severe itching caused by bile buildup. Researchers will trac…
Matched conditions: ALAGILLE SYNDROME
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New study tracks Real-World impact of itch drug for rare liver disease
Disease control Recruiting nowThis study follows 30 people with Alagille syndrome, a rare liver disease that causes severe itching, as they take the drug odevixibat (Bylvay) in their daily lives. Researchers want to see if the medicine helps them avoid surgery or a liver transplant and improves their growth. …
Matched conditions: ALAGILLE SYNDROME
Sponsor: Ipsen • Aim: Disease control
Last updated May 06, 2026 16:14 UTC